National Institute For Pharmaceutical Research And Development

What National Institute For Pharmaceutical Research And Development does

The National Institute for Pharmaceutical Research and Development (NIPRD) is a Federal Government parastatal of Nigeria operating under the Federal Ministry of Health. Established by Government Order No. 33 Vol. 74 of 11 June 1987 under the Science and Technology Act Cap 276 and made functional in 1989, it was transferred from the Federal Ministry of Science and Technology to the Federal Ministry of Health in 2001, accompanied by substantial investment in scientific equipment and human resources. NIPRD is the only institute of its kind in the West African region and is statutorily responsible for the research and development of drugs, vaccines, phytomedicines, commodities, and diagnostics aimed at improving sustainable access to safe, affordable, and high-quality healthcare in Nigeria.

NIPRD's core portfolio spans five integrated R&D areas — phytomedicine R&D (PT&RMD department), pharmaceutical drug development, vaccine R&D, diagnostics development, and biological products research — supported by an Analytical Laboratory Complex, a digital e-Herbarium platform cataloguing medicinal plants indigenous to Nigeria, clinical research capabilities, the NIPRD Consult advisory service, and education and training programmes. Its technology stack is anchored in physical laboratory infrastructure across multiple technical departments (microbiology/biotechnology, medicinal chemistry/quality control, medicinal plants research and traditional medicine, pharmaceutical technology, and pharmacology/toxicology) augmented by the digital e-Herbarium and the WHO PQ Capacity Building Programme, which provides technical enablement for Nigerian pharmaceutical companies to attain WHO Pre-Qualification.

The institute's business model is anchored on three revenue streams: government appropriations from the Federal Ministry of Health as a parastatal, fee-for-service consultancy and laboratory analysis engagements with pharmaceutical companies (including NIPRD Consult and WHO PQ support), and collaborative research grants from international and inter-governmental partners such as WHO, WAHO, USP, and Malaria Consortium. Customer segments comprise the Nigerian pharmaceutical manufacturing industry (primary), federal and state government health agencies, academic and research institutions, and traditional medicine practitioners and phytomedicine developers. Pricing is not publicly disclosed; engagements are negotiated on a per-project basis given the institutional/government character of the work.

Name

National Institute For Pharmaceutical Research And Development

Legal name

National Institute for Pharmaceutical Research and Development (NIPRD)

Website

https://niprd.gov.ng

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

1–10 employees

Short description

NIPRD is Nigeria's Federal Government parastatal under the Federal Ministry of Health, conducting statutory R&D on drugs, vaccines, phytomedicines, and diagnostics, and serving the Nigerian pharmaceutical industry, federal and state health agencies, academia, and traditional medicine practitioners with laboratory, consultancy, and capacity-building services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Research and Development Services

NAICS

Scientific Research and Development Services (5417), Public Administration (92)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industries

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA), Clinical Trial Supply, Logistics & Vendor Management FSP (HLAGAOAH), Disease-Specific Global Programs (HIV/TB/Malaria/NTDs) (HLAJAKAF)

Keywords

• Pharmaceutical research services
• Vaccine development
• Phytomedicine development
• Analytical laboratory services
• Drug discovery research

Headquarters

HQ city

Abuja

HQ country

Nigeria

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Government Funding and Appropriations: As a Federal Government parastatal under the Federal Ministry of Health, NIPRD is primarily funded through annual government appropriations and budgetary allocations from the Federal Government of Nigeria.
2. Pharmaceutical Industry Consultancy Services: Fee-for-service technical support, laboratory analyses, and consultancy engagements with pharmaceutical companies seeking WHO PQ capacity building and quality assurance.
3. Collaborative Research Grants: Funding received through collaborative research partnerships with international organizations, inter-governmental agencies, and development partners for specific R&D programmes.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

NIPRD is a government parastatal that conducts end-to-end research and development of drugs, vaccines, phytomedicines, commodities, and diagnostics, supported by an analytical laboratory complex and clinical research capabilities. It provides paid consultancy, laboratory analytical testing, and WHO PQ capacity-building services to pharmaceutical companies, and runs education/training programmes for researchers and industry professionals. The institute also partners with inter-governmental agencies, universities, and state governments on collaborative research projects targeting priority diseases in Nigeria.

Product overview

NIPRD operates as a multi-disciplinary research institute offering an integrated platform of pharmaceutical R&D services. The core portfolio spans five interconnected areas: phytomedicine R&D (via the PT&RMD department), pharmaceutical drug development, vaccine research, diagnostics development, and biological products. These core offerings are supported by specialized service modules including laboratory analytical services (with WHO Pre-qualification capacity building), clinical research capabilities, NIPRD Consult advisory services, and education/training programs. The institute functions as Nigeria's primary infrastructure for end-to-end pharmaceutical value chain development, from early-stage research through commercialization support.

Differentiator

Problem solved

Functional benefit

Products and services

• Phytomedicine Research & Development Research and development of phytomedicines derived from herbal/plant sources, including extraction, formulation, standardization, and clinical validation of traditional medicine products; supports the Ministerial Committee on Phytomedicine Commercialization.
• Pharmaceutical Drug Development End-to-end R&D for synthetic and semisynthetic pharmaceutical drugs targeting priority diseases in Nigeria, from discovery through formulation development.
• Vaccine Research & Development Full R&D capabilities for vaccine production including antigen development, formulation, and manufacturing to address priority diseases affecting Africa.
• Diagnostics Development Development of diagnostic tools and commodities for detection of diseases relevant to Nigeria and the African region.
• Biological Products Research Research and development of biological products including biopharmaceuticals and biological therapeutics.
• Laboratory Analytical Services Quality control and analytical testing services for pharmaceutical products, including WHO Pre-Qualification support to help pharma companies attain international standards.
• Clinical Research Services Clinical research capabilities for conducting trials on drugs, vaccines, and phytomedicines in development.
• NIPRD Consult Consultancy services offering expert guidance on pharmaceutical development, regulatory affairs, and technology transfer for the pharma industry.
• Education and Training Capacity building and professional development programs for pharmaceutical researchers and industry professionals.
• Collaborative Research Programs Partnership-based research initiatives with universities, government agencies, and international organizations on priority health challenges.

Quantifiable outcome

• WHO PQ Capacity Building Programme — technical support provided to pharmaceutical companies to attain WHO Pre-Qualification certification
• +1 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Federal University Teaching Hospital Lafia (FUTHL)coreStrategic or Co-development Partner · 1 January 2025NIPRD signed a Memorandum of Understanding (MoU) with Federal University Teaching Hospital Lafia, establishing a formal collaborative framework for clinical research, laboratory analyses, and joint R&D activities in pharmaceutical and biomedical sciences.
• World Health Organization (WHO)coreStrategic or Co-development PartnerNIPRD collaborates with WHO on the WHO PQ Capacity Building Programme, providing technical support to pharmaceutical companies in Nigeria to achieve WHO Pre-Qualification certification, enabling access to international medicines procurement markets.
• West African Health Organization (WAHO)coreStrategic or Co-development PartnerRegional inter-governmental health partnership through WAHO for harmonizing pharmaceutical standards, capacity building, and health technology assessment across West Africa.
• United States Pharmacopeia (USP)coreTechnology or IntegrationPartnership with USP (United States Pharmacopeia) for pharmaceutical quality standards, laboratory methodology, and capacity building to improve medicines quality in Nigeria.
• Malaria ConsortiumminorStrategic or Co-development PartnerCollaborative engagement with Malaria Consortium on research and development initiatives targeting malaria treatments and prevention products.
• Lagos State Government (Health Ministry)coreStrategic or Co-development PartnerHigh-level engagement with Lagos State Commissioner of Health and pharma industry stakeholders to address technology gaps in Nigeria's pharmaceutical and vaccine industries, and strengthen domestic manufacturing capacity.
• Katsina State GovernmentminorStrategic or Co-development PartnerInter-governmental collaboration with Katsina State Government on pharmaceutical and health-related research and development initiatives.
• Federal Ministry of Health, NigeriacoreStrategic or Co-development PartnerNIPRD operates as a parastatal under the Federal Ministry of Health, executing national pharmaceutical R&D policy and aligning with the Health Sector Renewal Programme and Presidential Unlocking Healthcare Value Chain Initiative.
• Senate Committee on Health (Secondary and Tertiary)coreStrategic or Co-development PartnerLegislative oversight and support from the Senate Committee on Health, with commitment to provide legislative backing to enable NIPRD's statutory functions.
• Presidential Health Sector Renewal InitiativecoreStrategic or Co-development PartnerActive participant in the Presidential 'Unlocking Healthcare Value Chain Initiative', optimizing end-to-end R&D pathways for addressing priority diseases in Nigeria.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Indian Council of Medical Research (ICMR): ICMR is India's apex body for biomedical research, formulation, and policy. It mirrors NIPRD's mandate of drug/vaccine/diagnostic R&D for national priorities but operates at vastly greater scale with established commercial translation pathways.
• Medical Research Council (MRC) UK: MRC is the UK's primary public funder of biomedical research. It is comparable to NIPRD as a publicly funded medical research institution with translational and capacity-building functions, though operating at far greater scale and through grant funding rather than in-house R&D.
• Pasteur Institute: The Pasteur Institute is a globally recognized nonprofit biomedical research organization with vaccine, diagnostics, and pharmaceutical R&D. It shares NIPRD's multi-disciplinary R&D and public-health orientation but at much greater scale and with global footprint.
• Oswaldo Cruz Foundation (Fiocruz): Fiocruz is Brazil's federally funded public health research and vaccine manufacturing institution. It is comparable to NIPRD as a publicly funded end-to-end pharma/biomedical R&D and vaccine producer, though at substantially greater scale and with manufacturing capability NIPRD lacks.

Regional players

• South African Medical Research Council (SAMRC): SAMRC is South Africa's statutory medical research council with a mandate spanning biomedical, clinical, and public health research. Comparable to NIPRD as a national public-sector R&D institution, but with materially larger funding scale and more mature commercial translation.
• Ethiopian Public Health Institute (EPHI): EPHI is Ethiopia's federal public health research institute with national reference laboratory functions. It overlaps with NIPRD in pharmaceutical/diagnostic quality assurance and public-sector R&D mandate within the African public health ecosystem.
• Kenya Medical Research Institute (KEMRI): KEMRI is Kenya's statutory body for medical research, with end-to-end R&D capabilities across pharmaceuticals, vaccines, and diagnostics. It is comparable to NIPRD in scope, mandate, and African public-sector R&D positioning, though serving a different national market.
• Council for Scientific and Industrial Research (CSIR, South Africa): CSIR is South Africa's statutory R&D council with biotech and pharmaceutical portfolios. Comparable to NIPRD's government-owned multidisciplinary R&D model, though covering a broader industrial mandate beyond health.
• Noguchi Memorial Institute for Medical Research: Ghana's premier biomedical research institute under the University of Ghana, with comparable vaccine, diagnostics, and pharmaceutical R&D capabilities. Operates in the same West African region with overlapping WHO and WAHO partnership networks.

Direct peers

• Nigerian Institute of Medical Research (NIMR): NIMR is a Federal Government parastatal under the Federal Ministry of Health focused on medical research in Nigeria. Like NIPRD, it is a publicly funded national research institute addressing communicable and non-communicable diseases, making it the closest domestic counterpart.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/NIPRD2
• Facebookfacebook.com/niprdnigeria
• LinkedInlinkedin.com/company/niprd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Institute For Pharmaceutical Research And Development